Receptor News and Research

RSS

RNA clue to MS disease course

Researchers say that the RNA profiles of peripheral blood mononuclear cells can identify two distinct subsets of patients with multiple sclerosis.

4 Oct 2012

Paroxetine shows promise against heart failure

A medication usually used to help treat depression and anxiety disorders has the potential to help prevent heart failure, according to researchers at the University of Michigan.

2 Oct 2012

Hormone and androgen receptor genes combined affect sperm motility

The combination of alleles for genes encoding the follicle-stimulating hormone receptor and androgen receptor has a significant impact on sperm motility, emphasising the importance of the genes in sperm quality, say Greek scientists.

1 Oct 2012

Multiple Epo doses with hypothermia offers neonate neuroprotection

Multiple doses of erythropoietin in combination with hypothermia could be neuroprotective in neonates with hypoxic‑ischemic encephalopathy, say researchers.

1 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Study opens new door to more personalized treatment of advanced breast cancer

For the first time, researchers have conducted a large trial in which they tested the entire genome of individual breast cancers to help personalize treatment. They released their findings at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

HR status defines two different subsets of HER2 positive cancers

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

1 Oct 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

Bioengineers design inexpensive, rapid medical diagnostic tests

By mimicking nature's own sensing mechanisms, bioengineers at UC Santa Barbara and University of Rome Tor Vergata have designed inexpensive medical diagnostic tests that take only a few minutes to perform.

29 Sep 2012

First Edition: September 28, 2012

Today's headlines include reports about political and policy-oriented health care developments.

28 Sep 2012

Three USU doctoral students to receive Henry M. Jackson Fellowships

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has selected three promising Uniformed Services University of the Health Sciences (USU) doctoral students to receive fellowships for the 2012-13 academic year. The program, established in 1988, includes two Henry M. Jackson Fellowships and one Val G. Hemming Fellowship. Each fellow receives a stipend and travel support.

28 Sep 2012

Researchers reduce life-threatening complication of stem cell transplants in mice with leukemia

Studying leukemia in mice, researchers at Washington University School of Medicine in St. Louis have reduced a life-threatening complication of stem cell transplants, the only curative treatment when leukemia returns.

28 Sep 2012

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.

28 Sep 2012

Researchers solve key part of muscle regeneration mystery

Working with mice, Johns Hopkins researchers have solved a key part of a muscle regeneration mystery plaguing scientists for years, adding strong support to the theory that muscle mass can be built without a complete, fully functional supply of muscle stem cells.

28 Sep 2012

Study explores effects of immunotherapy on malignant gliomas

In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different types of brain tissue, shedding light on why cancerous brain tumors are so difficult to treat.

28 Sep 2012